Skip Navigation

CAR T-Cell Therapy

  • Chimeric antigen receptor, or CAR T-cell therapy, is a new form of immunotherapy that uses specially altered T cells to more specifically target cancer cells. The immune system is made up of specific cells and organs that protect the body from infection and cancer. Among these are T cells, which hunt down and destroy abnormal cells, including cancer cells. Sometimes, cancer cells find ways to evade the immune system; so, the immune system needs to be retrained to recognize and attack cancer cells. CAR T-cell therapy is one innovative approach to program the immune system to attack cancer.

    After a sample of a patient's T cells has been collected from the blood, the cells are re-engineered so they sprout special structures called chimeric antigen receptors (CARs) on their surface. When these CAR T cells are reinjected into the patient, the receptors may help the T cells identify and attack cancer cells throughout the body.

    Currently, CAR T-cell therapy is FDA-approved as the standard of care for some forms of refractory non-Hodgkin lymphoma and pediatric relapsed acute lymphoblastic leukemia (ALL), and is available through clinical trials for other forms of blood cancer.

  • CAR T-Cell Therapy: How Does It Work?
    CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system’s inherent cancer-fighting powers. It involves treating patients with modified versions of their own immune system T cells ­– white blood cells that help protect the body from disease.

  • Dr. Caron Jacobson on CAR T-Cell Therapy Data
    Dana-Farber’s Caron Jacobson, MD, provides an update on the promising, long-term data presented on CAR T-cell therapy for non-Hodgkin lymphoma, multiple myeloma, and acute lymphoblastic leukemia.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).